TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients that do not have disease progression at 16 weeks from start of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment related adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of clinical signs measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in medicated diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Measure of psychologic stress of patients and staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measure of physiologic stress of patients and staff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center for Epidemiologic Studies Depression Scale for Children (CES-DC) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL) 4.0 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of difficult-to-treat and severe Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emergency Room Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Global myocardial ischemic load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Efficacy Failure (TTEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced 1 or More Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of Inguinal Hernia
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Patients Having Pain in the Post Operative Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial line pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DRD2 receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tetanus seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calcium Absorption Fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endurance time of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary tract complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in ADAS-cog-13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-PRP Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Meropenem concentration in Interstitial Lung Fluid (ILF) and Epithelial Lining Fluid (ELF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Pain Intensity Numerical Rating Scale (PI-NRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of anti-BKV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Disease Relapse(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ocular Itch Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migration rate of FCSEMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of Recurrence and Metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative number of newly active lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neck Retraction Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new non-melanoma skin cancer development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Glycosylated Hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of Toric Intraocular Lens Formulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intensity score of subjects' mimic facial emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valence score of subjects' mimic facial emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arousal score of subjects' mimic facial emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteraemia Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Exit Site Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Tunnelitis Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum decrease in the percentage baseline CO2 response slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zero-to-six hour area under the curve for the percentage baseline CO2 response slope profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Intraclass correlation coefficient of IOL power calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass correlation coefficient of various ocular biometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MNA score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Driving impairment effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement from baseline low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistency of Response and Non-response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Body Appreciation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: State Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abdomen circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in human microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Motivation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent vital bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent residual graft material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent fibrous tissue and marrow space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of 5-meter distance walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Pain Free Attack Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of N-Rephasin® SAL200
Endpoint domain: Adverse events/effects
Primary endpoint: Nutrition behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3 Dimensional volumetric analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: photographic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ganglion cell complex thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retinal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Substance use after discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of HPV types among women with invasive cervical cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of HPV types among women with squamous cell carcinoma
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Nitrite Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Unit Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uricase-PEG 20 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of desmoid tumors based on WHO criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate of desmoid tumors based on change in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate of desmoid tumors based on change in T2 signaling hyperintensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate of desmoid tumors based on RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants with successful surgical Placement and retrieval of Microdevice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serious Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Injection-site Complaints
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Exercise Endurance Time Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Outside Specified Blood Glucose Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to acquire POEM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reoperation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Platelet count greater than or = to 50,000
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of stress level of Health Care Professional - Salivary cortisol (ng/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay - days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Irritation Response Evaluation According to Erythema Scoring Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Allergic Reaction Evaluation According to Erythema Scoring Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average change in gallbladder size (volume by ultrasound)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average change in gallbladder function (ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Timed up and Go (TUG) Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economic Benefit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medication start/stop
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient involvement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in hematology and biochemistry laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delinquency
Endpoint domain: Adverse events/effects
Primary endpoint: school misbehavior
Endpoint domain: Adverse events/effects
Primary endpoint: aggression and violence
Endpoint domain: Adverse events/effects
Primary endpoint: school achievement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Core Muscle Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and duration of symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of depression assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of gastric and/or duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in cognitive ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in levels of anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of bacterial meningitis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of herpes simplex virus meningitis/encephalitis
Endpoint domain: Mortality/survival
Primary endpoint: motor symptoms (UPDRS Section III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease of V20 (lung)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: decrease of Dmax (breast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: decrease the duration of radiotherapy fractions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in number of Headaches Attributed to TMD (HA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Headache Impact Test-6 score (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in WOMAC Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients identified with lysosomal storage disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Episcleral Venous Pressure (EVP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: severity of post-thoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction abortion interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in mRNA expression of genes involved in cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extubation readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total sleep per night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of decursin, decursinol angelate (DA) and decursinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high sensitive C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Solicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration (Cmax) of hetrombopag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of hetrombopag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulative excretion rate of hetrombopag and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of positive lymph nodes removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Kinetic Symmetry (Lower Limbs Ground Reaction Forces)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events - Heart Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events - Change in Blood Pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Median FiO2 (%) needed to maintain oxygen saturation ≥94%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to weaning from high-flow nasal cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to breathing ambient (room) air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chimerism post-transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wave reflection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent residual diameter stenosis (%DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery rate of vestibular input in the Sensory Organization Test (SOT) at 2-months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate of the caloric test at 2-months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate of Cervical Vestibular Evoked Myogenic Potentials (cVEMP) at 2-months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole blood fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting plasma inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body composition (body fat, muscle mass, body weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sero-type specific antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disability at 36 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Received HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Reported Having Been Referred for Pre-exposure Prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Reported Having Actually Received a Prescription for Pre-exposure Prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: overall and diarrhea and pneumonia specific hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Subject withdrawals due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of EMG and SSEP testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of hypotension episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total pharyngeal airway space surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of positive pulmonary tuberculosis (PTB) tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment Probe Accuracy Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalization Probe Accuracy Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy or early response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in % neutrophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of VWF functional screening assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal Anemia at Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rates on the digital weekly questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response on the validation questionnaire at Baseline and at Week 26
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Workload of responding to the alerts on the weekly questionnaire for the care team
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical utility of the alerts for the care team
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Score on the Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes